Administrative Core
Administrative Core
批准号:
10398387
负责人:
JOSHUA J.C. ROSENTHAL
金额:
$66.65万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-23 至 2024-08-31
关键词:
AddressAdenosineAdultAffectAfferent NeuronsAmino AcidsAnalgesicsAnimal ModelAnimal TestingArchitectureAreaArginineAwardBCAR1 geneBase PairingBiologicalBiologyBudgetsCardiacCellsChargeClinical TrialsCodon NucleotidesCommunicationConflict (Psychology)ConsensusCore FacilityDNADataData AnalysesDevelopmentDiabetes MellitusDisease modelEffectivenessElectrophysiology (science)ElementsEnsureEnzymesEvaluation ResearchFDA approvedFinancial SupportFundingGeneticGeographyGoalsGrantGuanosineGuide RNAGuidelinesHeart DiseasesHumanInosineInstitutionIntellectual PropertyIonsLaboratoriesLeadLegalLogisticsLysineMalignant - descriptorMalignant NeoplasmsMessenger RNAModificationMonitorMotionNeuronsOverdosePainPain DisorderPatientsPeripheralPermeabilityPharmaceutical PreparationsPrevalenceProgress ReportsPropertyProperty RightsProtein IsoformsRNARNA EditingReagentRegulationReportingResearchResearch PriorityResearch SupportResource SharingResourcesServicesShunt DeviceSiteSodium ChannelStructureSupervisionSystemTexasTimeTimeLineUnited States National Institutes of HealthUniversitiesWorkWorkplaceaddictionarmbasechannel blockerschronic paincommercializationconflict resolutiondata managementdisabilitydsRNA adenosine deaminaseexperienceimmunogenicmeetingsmembernovelopioid abusepain modelprogramsside effectsmall moleculesuccesstargeted treatmentvoltage
中文摘要
慢性疼痛是致残的主要原因,全世界约三分之一的成年人受到影响,患病率
比心脏病、癌症和糖尿病的总和还要大。阿片类药物的滥用和滥用导致了
全国范围内的吸毒和吸毒过量危机。因此,迫切需要替代的、不会上瘾的止痛药。
非选择性电压门控钠通道(NAV)阻滞剂是FDA批准的现有非成瘾性药物之一
有时可以缓解患者症状的药物。然而,它们的应用受到中枢神经系统和
心脏副作用。人类疼痛障碍的遗传和功能研究以及疼痛的动物模型
有效的Nav1.7,一个电压门控的钠通道,优先在外周神经元中表达,作为一种
有吸引力的治疗目标。然而,选择异构体的NAV阻滞剂很难产生,而那些
已经产生的毒素迅速从体内清除,限制了它们的效力。另一种方法是
需要的。我们提出了一种新的、非上瘾的方法来治疗慢性疼痛,方法是编辑编码的消息
Nav1.7,以改变其电生理特性。通过将单个赖氨酸密码子改变为精氨酸
离子选择性过滤器,通道将从对Na+的选择性转变为对Na+和K+的选择性,有效地创造
一种会抑制兴奋性的逆流分流。
Site-Directed RNA Editing(SDRE)是指在RNA中生成程序化编辑的新机制。它
依赖于ADAR(作用于RNA的腺苷脱氨酶)酶,这些酶在体内表达
人类细胞,包括感觉神经元。在引导RNA(GRNA)的指导下,SDRE系统精确地转换
精选的腺苷为肌苷,这是鸟苷的翻译模拟物,可以重新编码特定的氨基酸。为
作为止痛药,编辑mRNA比编辑DNA更可取,因为它是暂时的,从而限制了潜在的脱靶
影响,包括恶性转化和ADAR是内源性的,而酶用于DNA操作
(例如,CaS蛋白)不具有免疫原性,因此SDRE不具有免疫原性。与小分子通道相比
阻滞剂,SDRE可以更具体,因为它依赖于靶向的Watson-Crick碱基配对的gRNA,
而且它的影响可能会持续更长时间,因为只要编辑过的频道被表达出来,它们就会一直存在。
我们建议使用SDRE编辑Nav1.7 K1395R,使通道对Na+和K+都可渗透。这个
行政核心的目的是建立一个行政结构,以支持项目的目标。
这包括跟踪科学里程碑的委员会和指导方针,解决
知识产权和其他领域,监督预算和财务,确保准确和及时
向美国国家卫生研究院报告。
英文摘要
Chronic pain is a leading cause of disability, affecting about one-third of adults worldwide, with a prevalence
greater than heart disease, cancer, and diabetes combined. Misuse and abuse of opiates have led to a
nationwide addiction and overdose crisis. Thus, there is an urgent need for alternative, non-addictive analgesics.
Non-selective voltage-gated sodium channel (Nav) blockers are among existing non-addictive FDA-approved
drugs which can sometimes provide symptomatic relief for patients. However, their utility is limited by CNS and
cardiac side effects. Genetic and functional studies of human pain disorders and animal models of pain have
validated NaV1.7, a voltage-gated Na Channel that is preferentially expressed in peripheral neurons, as an
attractive target for therapy. Isoform-selective Nav blockers, however, are difficult to generate and those that
have been generated are rapidly cleared from the body, limiting their effectiveness. Alternative approaches are
needed. We propose a novel, non-addictive approach to treat chronic pain by editing the messages that encode
NaV1.7 in order to alter its electrophysiological properties. By changing a single lysine codon to arginine in the
ion selectivity filter, the channel will go from being Na+ selective to both Na+ and K+ selective, effectively creating
a counter-current shunt that will dampen excitability.
Site-Directed RNA Editing (SDRE) refers to novel mechanisms to generate programmed edits within RNAs. It
relies on the ADAR (Adenosine Deaminase that Acts on RNA) enzymes, which are endogenously expressed in
human cells, including sensory neurons. Directed by a guide RNA (gRNA), SDRE systems convert precisely
selected adenosines to inosine, a translational mimic for guanosine, which can recode specific amino acids. For
use as an analgesic, editing mRNA is preferable to DNA because it is transient, thus limiting potential off-target
effects, including malignant transformations and ADARs are endogenous while enzymes for DNA manipulation
(e.g. Cas proteins) are not, thus SDRE will not be as immunogenic. Compared to small molecule channel
blockers, SDRE can be more specific, because it relies on Watson-Crick base-pairing of gRNAs for targeting,
and its effects are likely longer lasting because they will remain as long as the edited channels are expressed.
We propose to use SDRE to edit NaV1.7 K1395R to render the channel permeable to both Na+ and K+. The
purpose of the Administrative Core is to develop an administrative structure to support the goals of the project.
This includes committees and guidelines for keeping track of scientific milestones, resolving conflicts in
intellectual property and other areas, overseeing budgets and finances, and ensuring accurate and timely
reporting to the NIH.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development and Validation of Animal Models and/or Outcome Measures
-
批准号:10398390
-
项目类别:
-
资助金额:$85.73万
-
财政年份:2021
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Correction of Mutations Underlying Alternating Hemiplegia of Childhood by Site-Directed RNA Editing
-
批准号:10354983
-
项目类别:
-
资助金额:$45.65万
-
财政年份:2021
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Assay Development, Screening and Early Optimization
-
批准号:10398391
-
项目类别:
-
资助金额:$160.36万
-
财政年份:2021
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Center for Neuroplasticity at the University of Puerto Rico
-
批准号:8687677
-
项目类别:
-
资助金额:$213.59万
-
财政年份:2013
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
ACTIVITY #3 - ENHANCEMENT OF NEUROGENETICS RESEARCH AT THE INST OF NEUROBIOLOGY
-
批准号:8357162
-
项目类别:
-
资助金额:$20.21万
-
财政年份:2011
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Regulation of the Na/K Pump by RNA Editing
-
批准号:7885009
-
项目类别:
-
资助金额:$29.71万
-
财政年份:2010
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Regulation of the Na/K Pump by RNA Editing
-
批准号:8512811
-
项目类别:
-
资助金额:$28.71万
-
财政年份:2010
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Regulation of the Na/K Pump by RNA Editing
-
批准号:8702244
-
项目类别:
-
资助金额:$29.46万
-
财政年份:2010
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
ACTIVITY #3 - ENHANCEMENT OF NEUROGENETICS RESEARCH AT THE INST OF NEUROBIOLOGY
-
批准号:8166216
-
项目类别:
-
资助金额:$19.42万
-
财政年份:2010
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Regulation of the Na/K Pump by RNA Editing
-
批准号:8038271
-
项目类别:
-
资助金额:$29.11万
-
财政年份:2010
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Regulation of the Na/K Pump by RNA Editing
-
批准号:8311019
-
项目类别:
-
资助金额:$29.76万
-
财政年份:2010
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
ACTIVITY #3 - ENHANCEMENT OF NEUROGENETICS RESEARCH AT THE INST OF NEUROBIOLOGY
-
批准号:7959195
-
项目类别:
-
资助金额:$27.94万
-
财政年份:2009
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
ACTIVITY #3 - ENHANCEMENT OF NEUROGENETICS RESEARCH AT THE INST OF NEUROBIOLOGY
-
批准号:7715298
-
项目类别:
-
资助金额:$22.79万
-
财政年份:2008
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
ACTIVITY #3 - ENHANCEMENT OF NEUROGENETICS RESEARCH AT THE INST OF NEUROBIOLOGY
-
批准号:7561539
-
项目类别:
-
资助金额:$23.76万
-
财政年份:2007
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Regulation of the Na/K Pump by RNA Editing
-
批准号:7029764
-
项目类别:
-
资助金额:$34.85万
-
财政年份:2004
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
FUNCTIONAL EFFECTS OF RNA EDITING ON A KV1 K+ CHANNEL
-
批准号:6056009
-
项目类别:
-
资助金额:$3.92万
-
财政年份:2000
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Regulation of the Na/K Pump by RNA Editing
-
批准号:7558491
-
项目类别:
-
资助金额:$58.95万
-
财政年份:--
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Regulation of the Na/K Pump by RNA Editing
-
批准号:7312772
-
项目类别:
-
资助金额:$39.0万
-
财政年份:--
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Regulation of the Na/K Pump by RNA Editing
-
批准号:7367952
-
项目类别:
-
资助金额:$64.35万
-
财政年份:--
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
Regulation of the Na/K Pump by RNA Editing
-
批准号:7774307
-
项目类别:
-
资助金额:$57.01万
-
财政年份:--
-
负责人:JOSHUA J.C. ROSENTHAL
-
依托单位:
国内基金
海外基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
-
批准号:82074359
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:安晓飞
-
依托单位:
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
-
批准号:81570244
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:丁兆平
-
依托单位:
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
-
批准号:81171113
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2011
-
负责人:黄文
-
依托单位: